Celgene, Google ante up for Armo's next-gen IL-10/PD-1 immuno-oncology combos

Well along in the clinic with a mix of second-wave immuno-oncology programs in early-stage studies, Armo BioSciences has lined up $50 million in funding to pay for pivotal stage development.

Beth Seidenberg at Kleiner Perkins Caufield & Byers led the way on the round, joined by OrbiMed, DAG Ventures and NanoDimension, as well as new investors HBM Healthcare Investments, GV (formerly Google Ventures), Celgene ($CELG), Industrial Investors Group and Clough Investment Partners.

They're backing a Redwood City, CA-based company that has carefully gathered the IP around an IL-10 drug in-licensed from Merck, which had in turn acquired the program in its big Schering-Plough buyout. AM0010  is supposed to help sensitize tumors for an immune system assault, a vulnerability that they are now pursuing with combos that include their newly acquired PD-1 checkpoint program.

"In our perspective, the first wave of immuno-oncology is set," says CEO Peter Van Vlasselaer. The first generation of checkpoint inhibitors clearly help a significant portion of cancer patients, he notes. But there are plenty of opportunities for those who can do better for a much broader patient group, with a strategy that is also designed to advance a new approach that the CEO believes can be much safer and more tolerable for patients. And that's where Armo intends to play.

The $50 million C round gives Armo enough cash to make it until the end of 2017, completing its range of early stage studies and positioning the company for upcoming Phase II/III studies that they can take to regulators.

One way the IL-10 lead drug works is by priming cancer cells for an attack by a swarm of targeted, tumor-specific T cells. It's a hot field, and one that has kept its syndicate's interest as the company sets the stage for a pivotal assault on registration-worthy data. A year ago that would have been a sure recipe for an IPO, but in this turbulent market, the CEO is keeping his options open about funding in the future.

"I think that in the last 6 months, there are not a lot of crystal balls that worked very well," says Van Vlasselaer.

- here's the release

Suggested Articles

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.

Annexon Biosciences and AlloVir are seeking a $100 million IPO apiece in a buoyant market that shows no signs of slowing down.